SynVest was incorporated in August 2024 as a C-Corp in DE. The mission of Synvest is to commercialize an important SV2A targeted PET tracer for types of neuro-degenerative disease including AD, FTD and others. The technology was based on more than decades of solid work at Yale University with US patent granted and clinical data available in AD and FTD. Heading to FDA approval will make this tracer commercially scalable and available for multi-centers clinical routine adoption even without Cyclotron on site and benefit more patients.